Cargando…
Chondrosarcoma-from Molecular Pathology to Novel Therapies
SIMPLE SUMMARY: Chondrosarcoma (CHS) belongs to a broad group of sarcomas and is the second most frequent malignant bone tumor. Due to its resistance to chemo- and radiotherapy, treatment of this tumor is complicated and is mainly limited to surgery. In this review, we described the characteristics...
Autores principales: | Zając, Agnieszka E., Kopeć, Sylwia, Szostakowski, Bartłomiej, Spałek, Mateusz J., Fiedorowicz, Michał, Bylina, Elżbieta, Filipowicz, Paulina, Szumera-Ciećkiewicz, Anna, Tysarowski, Andrzej, Czarnecka, Anna M., Rutkowski, Piotr |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155983/ https://www.ncbi.nlm.nih.gov/pubmed/34069269 http://dx.doi.org/10.3390/cancers13102390 |
Ejemplares similares
-
Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials
por: Zając, Weronika, et al.
Publicado: (2023) -
Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials
por: Dudzisz-Śledź, Monika, et al.
Publicado: (2023) -
Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies
por: Stachyra, Karolina, et al.
Publicado: (2021) -
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence
por: Borkowska, Aneta Maria, et al.
Publicado: (2022) -
Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation
por: Płachta, Iga, et al.
Publicado: (2021)